SCHEDULE 13G/A: EcoR1 Capital Discloses 4.0% Passive Stake in HOOKIPA Pharma Inc.
Beneficial Ownership Statement
EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has filed an amended Schedule 13G disclosing a passive beneficial ownership of 4.0% in HOOKIPA Pharma Inc.'s common stock as of December 31, 2024.
Summary
- EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 388,861 shares of HOOKIPA Pharma Inc. common stock, representing 4.0% of the class.
- EcoR1 Capital Fund Qualified, L.P. beneficially owns 367,227 shares, representing 3.8% of the class.
- The percentages are calculated based on 9,655,022 shares of Common Stock outstanding as of November 11, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of HOOKIPA Pharma Inc.
- EcoR1 Capital, LLC serves as the general partner and investment adviser for investment funds, including Qualified Fund, and Oleg Nodelman is the control person of EcoR1 Capital, LLC.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
The document does not contain any forward-looking statements or guidance from HOOKIPA Pharma Inc. management.
Industry Context
This filing is a routine disclosure of passive beneficial ownership by an investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape for HOOKIPA Pharma Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive institutional ownership in HOOKIPA Pharma Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarter for which HOOKIPA Pharma Inc. filed its Form 10-Q, reporting shares outstanding. |
| 2024-11-11 | Date on which 9,655,022 shares of Common Stock were reported as outstanding by the Issuer. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership threshold). |
| 2025-02-14 | Date of filing of the Schedule 13G Amendment No. 2. |
Keywords
HOOKIPA Pharma Inc., EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.